Short-duration therapy for respiratory tract infections

Annals of Pharmacotherapy

Volumn 38, Issue 9 SUPPL., 2004, Pages

  Goff, Debra A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFADROXIL; CEFDINIR; CEFIXIME; CEFPODOXIME PROXETIL; CEFTIBUTEN; CEFUROXIME; CEFUROXIME AXETIL; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; GATIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PENICILLIN DERIVATIVE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; ERADICATION THERAPY; HUMAN; INFECTION RISK; MAXILLARY SINUS; OTITIS MEDIA; PATIENT COMPLIANCE; PATIENT SELECTION; PHARMACODYNAMICS; PHARYNGITIS; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; TONSILLITIS; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; HUMANS; POPULATION SURVEILLANCE; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME;

EID: 4143096930     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E219     Document Type: Conference Paper

References (40)

1. Song JH. Introduction: the goals of antimicrobial therapy. Int J Infect Dis 2003;7(suppl 1):S001-3.
2. Chodosh S, Schreurs A, Siami G, Barkman HW Jr, Anzueto A, Shan M, et al., and the Bronchitis Study Group. Efficacy of oral ciprofloxacin vs. clarithromycin for treatment of acute bacterial exacerbations of chronic bronchitis. Clin Infect Dis 1998;27:730-8.
3. Quintiliani R. Clinical management of respiratory tract infections in the community: experience with telithromycin. Infection 2001;29(suppl 2):16-22.
4. Pichicero M. Short courses of antibiotic in acute otitis media and sinusitis infections. J Int Med Res 2000;28(suppl 1):25A-36A.
5. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
6. Bergman AB, Werner RJ. Failure of children to receive penicillin by mouth. N Engl J Med 1963;268:1334-8.
7. Reyes H, Guiscafre H, Muñoz O, Perez-Cuevas R, Martinez H, Gutierrez G. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997;50:1297-304.
8. Hoppe JE, Blumenstock G, Grotz W, Selbmann HK. Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey. Pediatr Infect Dis J 1999;18:1085-91.
9. Guillemot D, Carbon C, Balkau B, Geslin P, Lecoeur H, Vauzelle-Kervroëdan F, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998;279:365-70.
10. Schrag SJ, Peña C, Fernández J, Sánchez J, Gómez V, Pérez E, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001;286:49-56.
11. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001;48 (suppl T1):9-23.
12. Drusano G. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin Microbiol Infect 2001;7(suppl 3):24-9.
13. Shain CS, Amsden GW. Telithromycin: the first of the ketolides. Ann Pharmacother 2002;36:452-64. DOI 10.1345/aph.1A038
14. Felmingham D, Reinert RR, Hirakata Y, Rodloff A. Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and comparative in vitro activity of the ketolide, telithromycin. J Antimicrob Chemother 2002;50(suppl S1):25-37.
15. Nagai K, Hoellman D, Davies T, Jacobs M, Appelbaum P. Activity of telithromycin against 26 quinolone-resistant pneumococci with known quinolone-resistance mechanisms. Clin Microbiol Infect 2001;7:703-5.
16. Williams JW Jr, Holleman DR Jr, Samsa GP, Simel DL. Randomized controlled trial of 3 vs 10 days of trimethoprim/sulfamethoxazole for acute maxillary sinusitis. JAMA 1995;273:1015-21.
17. Pichichero ME, Cohen R. Shortened course of antibiotic therapy for acute otitis media, sinusitis and tonsillopharyngitis. Pediatr Infect Dis J 1997;16:680-95.
18. Casiano RR. Azithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Am J Med 1991;91(suppl 3A):27S-30S.
19. DeAbate CA, Heyder A, Leroy B, Sidarous E, Backstrom J. Oral telithromycin (HMR 3647; 800 mg od) for 5 days is well tolerated and as effective as cefuroxime axetil (500 mg bid) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB) (abstract 2228). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000:471.
20. Aubier M, Aldons PM, Leak A, McKeith DD, Leroy B, Rangaraju M, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med 2002;96:862-71.
21. Tellier G, Lasko B, Leroy B, Sidarous E, Andrade C. Oral telithromycin (HMR 3647; 800 mg od) for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid (500/125 mg tid) for 10 days in acute maxillary sinusitis (AMS) in adults (abstract 2226). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000:471.
22. Roos K, Brunswig-Pitschner C, Kostrica R, Pietola M, Leroy B, Rangaraju M, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy 2002;48:100-8.
23. Tellier G, Rangaraju M, Leroy B, Nusrat R. Telithromycin is efficacious for the treatment of acute maxillary sinusitis in patients of special interest (poster L-1381). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14-17, 2003.
24. Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community-acquired pneumonia (abstract L-373). Presented at: 42nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27-30, 2002:346.
25. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998;17:828-33.
26. Schönwald S, Kuzman I, Oreskovic K, Burek V, Skerk V, Car V, et al. Azithromycin: single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome - a randomized study. Infection 1999;27:198-202.
27. Pakistan Multicentre Amoxicillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002;360:835-41.
28. Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995;273:957-60.
29. Fogarty CM, Bettis RB, Griffin TJ, Keyserling CH, Nemeth MA, Tack KJ. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2000;45:851-8.
30. Guest N, Langan CE. Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis. Int J Antimicrob Agents 1998;10:49-54.
31. Bennett JB, Crook SJ, Shaw EJ, Davies RJ. A randomized double blind controlled trial comparing two amoxycillin regimens in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 1988;21:225-32.
32. Gotfried MH, DeAbate CA, Fogarty C, Mathew CP, Sokol WN. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis. Clin Ther 2001;23:97-107.
33. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001;18:503-12.
34. Schaberg T, Ballin I, Huchon G, Bassaris H, Hampel B, Reimnitz P. A multinational, multicentre, non-blinded, randomized study of moxifloxacin oral tablets compared with co-amoxiclav oral tablets in the treatment of acute exacerbation of chronic bronchitis. J Int Med Res 2001;29:314-28.
35. Beghi G, Berni F, Carratu L, Casalini A, Consigli G, D'Anto M, et al. Efficacy and tolerability of azithromycin versus amoxicillin/clavulanic acid in acute purulent exacerbation of chronic bronchitis. J Chemother 1995;7:146-52.
36. Hoepelman IM, Möllers MJ, van Schie MH, Greefhorst AP, Schlösser NJJ, Sinninghe Damste EJ, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1998;9:141-6.
37. Zithromax (full US prescribing information). Revised October 2003. www.pfizer.com/download/uspi_zithromax600mg.pdf (accessed 2004 Jun 14).
38. Cohen R, Levy C, Doit C, De La Rocque F, Boucherat M, Fitoussi F, et al. Six-day amoxicillin vs. ten-day penicillin V therapy for group A streptococcal tonsillopharyngifis. Pediatr Infect Dis J 1996;15:678-82.
39. Block SL, Kratzer J, Nemeth MA, Tack KJ. Five-day cefdinir course vs. ten-day cefprozil course for treatment of acute otitis media. Pediatr Infect Dis J 2000;19(12 suppl):S147-52.
40. Pessey JJ, Gehanno P, Thoroddsen E, Dagan R, Leibovitz E, Machac J, et al. Short course therapy with cefuroxime axetil for acute otitis media: results of a randomized multicenter comparison with amoxicillin/clavulanate. Pediatr Infect Dis J 1999;18:854-9.